Media headlines about BioTelemetry (NASDAQ:BEAT) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.3489881700535 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Lookout for Volatility – BioTelemetry, Inc., (NASDAQ: BEAT) – Stock Watch (stocksnewstimes.com)
- $0.21 Earnings Per Share Expected for BioTelemetry, Inc. (BEAT) This Quarter (americanbankingnews.com)
- BG Medicine (BGMD) & BioTelemetry (BEAT) Financial Review (americanbankingnews.com)
- Analysts Set Expectations for BioTelemetry, Inc.’s FY2017 Earnings (BEAT) (americanbankingnews.com)
- Oversold Conditions For BioTelemetry (BEAT) (thestreet.com)
Several equities research analysts have commented on the stock. Dougherty & Co reaffirmed a “buy” rating and set a $40.00 price objective on shares of BioTelemetry in a report on Wednesday, November 8th. Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. Raymond James Financial, Inc. assumed coverage on shares of BioTelemetry in a report on Thursday, October 26th. They set an “outperform” rating and a $37.00 price objective on the stock. SunTrust Banks, Inc. assumed coverage on shares of BioTelemetry in a report on Monday, October 23rd. They set a “buy” rating and a $41.00 price objective on the stock. Finally, Off Wall Street assumed coverage on shares of BioTelemetry in a report on Friday, September 15th. They set a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $42.86.
Shares of BioTelemetry (NASDAQ BEAT) traded up $0.30 on Friday, hitting $25.55. The stock had a trading volume of 496,704 shares, compared to its average volume of 476,642. BioTelemetry has a 12-month low of $18.60 and a 12-month high of $39.20. The company has a market capitalization of $782.66, a PE ratio of 33.84, a PEG ratio of 1.54 and a beta of 0.58. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The company had revenue of $81.02 million for the quarter, compared to the consensus estimate of $82.10 million. During the same quarter in the prior year, the company earned $0.21 earnings per share. The company’s quarterly revenue was up 52.7% on a year-over-year basis. equities analysts expect that BioTelemetry will post 0.83 earnings per share for the current year.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.